{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CHF", "regularMarketChangePercent": 1.2383949, "regularMarketPrice": 8.175, "earningsTimestamp": 1690261200, "earningsTimestampStart": 1690261200, "earningsTimestampEnd": 1690261200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -4.69, "epsForward": -2.61, "epsCurrentYear": -3.83, "priceEpsCurrentYear": -2.1344647, "sharesOutstanding": 177914000, "bookValue": -4.835, "fiftyDayAverage": 10.2574, "fiftyDayAverageChange": -2.0823994, "fiftyDayAverageChangePercent": -0.20301436, "twoHundredDayAverage": 13.20185, "twoHundredDayAverageChange": -5.0268497, "twoHundredDayAverageChangePercent": -0.3807686, "marketCap": 1454446976, "forwardPE": -3.132184, "priceToBook": -1.6907963, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "3.2 - Hold", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1497596400000, "priceHint": 2, "marketState": "REGULAR", "exchange": "EBS", "shortName": "IDORSIA N", "longName": "Idorsia Ltd", "messageBoardId": "finmb_418070523", "exchangeTimezoneName": "Europe/Zurich", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "ch_market", "esgPopulated": false, "regularMarketChange": 0.10000038, "regularMarketTime": 1683881585, "regularMarketDayHigh": 8.185, "regularMarketDayRange": "7.95 - 8.185", "regularMarketDayLow": 7.95, "regularMarketVolume": 30216, "regularMarketPreviousClose": 8.075, "bid": 8.145, "ask": 8.185, "bidSize": 0, "askSize": 0, "fullExchangeName": "Swiss", "financialCurrency": "CHF", "regularMarketOpen": 8.12, "averageDailyVolume3Month": 553372, "averageDailyVolume10Day": 530886, "fiftyTwoWeekLowChange": 0.33500004, "fiftyTwoWeekLowChangePercent": 0.042729598, "fiftyTwoWeekRange": "7.84 - 17.85", "fiftyTwoWeekHighChange": -9.675, "fiftyTwoWeekHighChangePercent": -0.5420168, "fiftyTwoWeekLow": 7.84, "fiftyTwoWeekHigh": 17.85, "dividendDate": 1602547200, "symbol": "IDIA.SW"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Hegenheimermattweg 91", "city": "Allschwil", "zip": "4123", "country": "Switzerland", "phone": "41 58 844 10 10", "website": "https://www.idorsia.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jean-Paul  Clozel M.D.", "age": 67, "title": "CEO & Exec. Director", "yearBorn": 1955, "fiscalYear": 2022, "totalPay": {"raw": 1375241, "fmt": "1.38M", "longFmt": "1,375,241"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andr\u00e9 C. Muller", "age": 59, "title": "Exec. VP & CFO", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Martine  Clozel", "age": 67, "title": "Exec. VP & Chief Scientific Officer", "yearBorn": 1955, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andrew C. Weiss", "age": 54, "title": "Sr. VP and Head of Investor Relations & Corp. Communications", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Julien  Gander L.L.M.", "age": 43, "title": "Sr. VP, Group Gen. Counsel & Company Sec.", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexander  Khatuntsev", "age": 44, "title": "Sr. VP & Head of Global HR", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Guy  Braunstein M.D.", "age": 66, "title": "Exec. VP & Chief Medical Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Simon  Jose", "age": 57, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Olivier  Lambert", "age": 56, "title": "Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Markus A. Riederer", "age": 60, "title": "Sr. VP & Head of Drug Discovery Biology", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 2, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}